Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1 |
Presented at International Conference on Opioids 2017
Abstract
Post-market surveillance data indicate low abuse levels of tapentadol products,
but research regarding the route of administration profile of tapentadol abusers is
limited. Our analyses evaluated abuse and routes of administration of tapentadol
within a sample of 270,695 adults assessed for substance abuse problems during
January 2012 through September 2016.